Lazard Asset Management
VIVO

Lazard Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Lazard Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,070
Closed -$135K – 2632
2022
Q4 		$135K Buy
+4,070
New +$131K ﹤0.01% 1410
2022
Q3 		– Sell
-3,909
Closed -$118K – 2619
2022
Q2 		$118K Buy
3,909
+3,881
+13,861% +$105K ﹤0.01% 1456
2022
Q1 		$0 Sell
28
-3,703
-99% -$88.1K ﹤0.01% 2600
2021
Q4 		$76K Buy
3,731
+358
+11% +$6.87K ﹤0.01% 1549
2021
Q3 		$64K Sell
3,373
-51
-1% -$1.02K ﹤0.01% 1571
2021
Q2 		$75K Sell
3,424
-5,356
-61% -$114K ﹤0.01% 1435
2021
Q1 		$230K Buy
8,780
+3,423
+64% +$81.4K ﹤0.01% 1080
2020
Q4 		$100K Sell
5,357
-48
-0.9% -$896 ﹤0.01% 1182
2020
Q3 		$91K Sell
5,405
-228
-4% -$4.43K ﹤0.01% 1041
2020
Q2 		$131K Buy
5,633
+22
+0.4% +$319 ﹤0.01% 968
2020
Q1 		$47K Buy
5,611
+3,459
+161% +$29.1K ﹤0.01% 1206
2019
Q4 		$21K Buy
2,152
+197
+10% +$1.85K ﹤0.01% 1224
2019
Q3 		$18K Buy
+1,955
New +$20.6K ﹤0.01% 1110

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Lazard Asset Management's VIVO Position: Q1 2023 in Review

Lazard Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 4,070 shares — an estimated $135K sold.

Lazard Asset Management first reported a position in VIVO in Q3 2019 and held it in 13 quarters. The position peaked at $230K in Q1 2021. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Lazard Asset Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Lazard Asset Management sold 4,070 Meridian Bioscience Inc shares in Q1 2023, an estimated $135K.
  • Lazard Asset Management first reported a position in Meridian Bioscience Inc in Q3 2019 and held it in 13 quarters.
  • Lazard Asset Management's Meridian Bioscience Inc position peaked at $230K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Lazard Asset Management's 13F filing for Q1 2023, filed 15 May 2023.